Dr. Escher added, "These exciting results provide the basis to proceed into clinical development later this year. Based on these pharmacodynamic properties, in combination with the reported concentrations of relevant cytokines from patients, we are confident that we can hit the therapeutic window in the chosen ophthalmic indication."
About Antibody Fragments
Antibody fragments are an emerging area of focus within the monoclonal antibody market and represent a new class of therapeutics. Due to their smaller molecular size, antibody fragments have a number of advantages over whole antibodies. Antibody fragments comprise only the naturally occurring antigen-binding pocket of the monoclonal antibody, and not the Fc part that is required to trigger an immune response. This new class of new products opens applications which are advantageous compared to monoclonal antibodies in indications where no such immune response is required. Thus, endogenous proteins are preferred targets for these new biologics.
About ESBATech AG
ESBATech AG is a Zurich, Switzerland-based, privately held drug
discovery and development company focused on advancing antibody fragments
for therapeutic applications. The company applies its proprietary, fully
human single-chain antibody frameworks to generate product candidates
against targets of clinical relevance. ESBATech is focused on delivering
high concentrations of its therapeutic antibody fragments to the targeted
sites, in combination with extremely low systemic load, in order to achieve
low risk of systemic drug reactions using topical and local delivery.
Current venture investors include SV Life Sciences, Clarus Ventures, HBM
BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest and VI
Partners. For more information about ESBATech, please visit,
|SOURCE ESBATech AG|
Copyright©2008 PR Newswire.
All rights reserved